Table 3. Immunogenicity of Hecolin^® in HBsAg (+) and HBsAg (-) participants.

Anti-HEV IgG status	HBsAg (+)	HBsAg (-)	P value
Baseline
Number	309	5,258
No. +ve (rate, %)&	144 (46.60)	2,515 (47.83)	0.6740
GMC (95% CI, Wu/ml)*	0.53 (0.43, 0.65)	0.54 (0.51, 0.56)	0.8752
Antibody response
Seroconversion rate (95% CI, %)
All	98.38 (96.26,99.47)	98.69 (98.34,98.98)	0.6053
Baseline anti-HEV (+)	96.53 (92.08, 98.86)	97.46 (96.76, 98.03)	0.4207
Baseline anti-HEV (-)	100.00 (97.79, 100.00)	99.82 (99.58, 99.94)	1.0000
GMC on 7 mo (95%CI, Wu/ml)*
All	19.32 (17.68, 21.12)	19.00 (18.59, 19.42)	0.7271
Baseline anti-HEV (+)	25.33 (22.74, 28.21)	24.71 (24.14, 25.29)	0.6283
Baseline anti-HEV (-)	15.25 (13.42, 17.34)	14.94 (14.44, 15.45)	0.7712

^&No of participants who had baseline positive anti-HEV IgG, the ratio in the parenthesis is the positive rate in this group. *GMC, geometric mean concentration.